SAN DIEGO and SUZHOU, China, July 07, 2026 (GLOBE NEWSWIRE) — Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has cleared the Company’s clinical trial application for ART5, a first-in-class up-regulating antisense oligonucleotide (ASO) therapeutic candidate for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The first-in-human study is expected to initiate in Q3 2026.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
